CA-MOVIUS
22.9.2020 17:02:11 CEST | Business Wire | Press release
Movius , the leading global provider of mobile unified communication software, is now enabling enterprises to securely and compliantly communicate with clients on their preferred mobile messaging channel. Today, the company announced the integration of WhatsApp support from within Movius MultiLine, their secure mobile communication service that can be deployed over any smartphone device on any global carrier. The integration will help unify and capture all business voice and messaging channels through a single integrated user experience, while enabling firms to effortlessly meet regulatory and surveillance needs.
An open Beta for this integration is available now and general availability is expected in the fourth quarter, 2020. As users continue to work remotely, they will find the expanded enterprise service provides unmatched productivity anywhere – and compliance everywhere – especially as companies accelerate their emerging Bring Your Own Device (BYOD) strategies and implementations.
WhatsApp users will experience a single, global solution that auto-archives in accordance with regulation and surveillance protocols – improving customer engagement for users, while simultaneously putting to rest any compliance gap concerns for the enterprise. This expansion of the MultiLine service, which integrates messaging, voice and compliance into enterprise workflows, lets Movius users leverage existing communications preferences and increase productivity – no matter where they are.
As digital transformation continues to accelerate, customers are quickly adapting to new mobile channels and expect the solutions that support them to do the same. With the rising popularity of services like WhatsApp – with two billion users worldwide – firms run the risk of unsanctioned use from their employees as they interact with clients. Or, by sanctioning a “no WhatsApp policy,” they risk alienating customers that prefer WhatsApp as their way to connect. Not only can data become unsafe when WhatsApp is used on personal devices, but the encryption makes it difficult to monitor and supervise activity, a necessary record-keeping oversight for regulated industries.
“We see this as an opportunity for enterprises to effectively leverage the business side of WhatsApp, endeavoring to bring that form of communication in the realm of compliance, supervision and client affinity, rather than banning and restricting the use of a popular way to connect,” said Movius Chief Product and Technology Officer, Amit Modi. “This is how enterprises are communicating and what their clients are demanding, and we stand by our mission to provide enterprises with compliant, reliable mobile communications that enable employees to communicate with clients whether they are sitting desk side or working remotely.”
With this integration, customers can engage with voice, text and WhatsApp all through a single interface, while allowing firms to have complete ownership and visibility into business conversations. Bringing these forms of communication into one place also allows for complete separation of business and personal correspondence among BYOD users, allowing firms to ensure their business data is protected and employees’ personal data remains private and untouched.
To learn more and request Beta access, click here: www.moviuscorp.com/whatsapp . Interested parties can also join webinars on the WhatsApp integration starting October 6; learn more about those here: https://moviuscorp.com/product-webinar-introducing-movius-whatsapp-messaging-connector/ .
About Movius
Movius is the leading global provider of mobile unified communications for the new world of work, offering productivity anywhere and compliance everywhere. Movius software and services integrate messaging, voice and compliance into enterprise workflows which helps organizations like JP Morgan Chase & Co, UBS, Jefferies, BCG Partners and Cantor Fitzgerald deliver better engagement for their clients. Enterprises around the world use the company’s all-in-one mobility platform to connect with their customers in more convenient, cost-effective and compliant ways.
The platform offers an easy way to extend and integrate voice, text, and messaging services into other systems, like CRM or collaboration tools. Movius recently released several new product capabilities, including WhatsApp support and integration with Salesforce CRM. These capabilities deliver additional customer value and can elevate the role MultiLine plays in customer organizations.
Headquartered in Atlanta, Movius has additional locations in Silicon Valley, Calif., and Bangalore, India. Movius works with leading global partners like T-Mobile, BlackBerry, BT Global, Telstra, and Telefónica. For more information on Movius, visit https://www.moviuscorp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005730/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom